Schizophrenia treatment acceptance response trial: a 20-week, open-label, multicenter, randomized study comparing the effect of the 'gain acceptance approach verses the 'approach-as-usual' in supporting patient acceptance of long-acting risperidone (Risperdal Consta) in adults with schizophrenia
Phase of Trial: Phase IV
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen
- 06 Apr 2010 Actual patient number (650) added as reported by ClinicalTrials.gov.
- 26 Apr 2008 New trial record.